1. ¹Internal Medical Clinic I, University Hospital, Copenhagen NV, Denmark
2. ²Department of Internal Medicine M, Glostrup University Hospital, Glostrup, Denmark

Correspondence: L Behrend, Internal Medical Clinic I, Bispebjerg University Hospital, Bispebjerg Bakke 23, Copenhagen NV 2400, Denmark. E-mail: lb19@bbh.hosp.dk

Received 4 November 2004; Revised 1 December 2004; Accepted 8 December 2004; Published online 27 January 2005.

Abstract

The objective of this study is to describe the eligibility, consumption, efficacy and patient satisfaction when treating men with diabetes with Sildenafil. The study is a prospective, self-reported, flexible-dose study. In total, 45 patients with diabetes (type 1 or 2), complaining of erectile dysfunction, were treated with Sildenafil over a 12-week period. Efficacy was assessed using a patientlog, a general satisfaction questionnaire and the International Index of Erectile Function (IIEF). Of 326 men, 192 reported erectile dysfunction, 79 did not fulfil the criteria for Sildenafil treatment and 49 declined to participate. In the group of 33 (age 45–75 y, means.d.: 58.17.2) completing the study, erectile function was significantly improved (P<0.0001). A total of 12 patients (36.4%) experienced no treatment effect at all. Eligibility and desire for treatment was low. Sildenafil is far from being a 'cure all' in the treatment of ED in diabetes.